Virinx

Virinx is a private U.S. medical device and healthcare technology company developing highly integrated electronic micro-modules for diagnosis and treatment applications. Publicly available information indicates the company is focused on portable, small-footprint, low-cost medical and healthcare systems rather than traditional drug development. Its most visible disclosed program is Viper22, a miniature noncontact system being evaluated for suppression of wound-infecting bacteria and fungal infections such as onychomycosis. The company has described preliminary nonclinical results and stated that it is pursuing in-vivo evaluation for wound-management uses. Overall, Virinx appears to be an early-stage medtech company operating at the intersection of IoT-enabled hardware and infection-management applications.